Role of Tivozanib in Renal Cell Carcinoma (RCC) - Episode 3
Dr Thomas Hutson reviews the adverse event profile of tivozanib and provides advice to community oncologists on how to best manage these toxicities.
Related Content:
‘Key Signs’ of Cytokine Release Syndrome to Know
FDA Grants Fast Track Designation to CTX-009 in Biliary Tract Cancer
A Cancer Drug that Impacted My Life for SLL
Meg Bennett Died, ‘Star Trek’ Actress Still Cancer-Free After 20 Years and More